Metabolic Dysfunction-associated Steatotic Liver Disease, Type 2 Diabetes Mellitus
Conditions
Keywords
Comorbid MASLD and T2DM, Intermittent energy restriction
Brief summary
This study aims to explore the efficacy of CMNT, an intermittent energy restriction (iER) intervention, in managing Chinese adults with type 2 diabetes and non-alcoholic fatty liver disease. An interim analysis will be added to the planned 120-participant CMNT intervention program to compare intervention efficacy with the usual care control group and assess potential risks associated with dietary interventions.
Detailed description
Study Protocol Amendments (v3.0) are as follows: 1. Addition of Interim Analysis. Rationale: The purpose of adding an interim analysis is to evaluate the effectiveness of the CMNT dietary intervention during this clinical trial, while also assessing participant compliance and the safety of the energy-restricted diet. 2. Expansion of BMI Inclusion Criteria. The BMI inclusion criterion was revised from 18-35 to \> 18 (removing the upper limit) to include patients with higher BMI values. Rationale: In clinical practice, some patients with a BMI over 35 have shown interest in participating in this study. After evaluation by physicians, these patients can be included. 3. Increase in the Number of Multicenter Sites. The number of centers increased from 3 to 6. Rationale: Expanding the number of multicenter sites accelerates participant recruitment. Given the study's focus on patients with T2D and NAFLD, the recruitment of patients with comorbidities is relatively challenging. Additionally, expanding the number of centers enhances the generalizability of the study's conclusions, making them applicable to patients in more regions. 4. Clarification and Revision of Secondary Objectives and Corresponding Evaluation Criteria. Addition of metabolomics content to identify key metabolites in CMNT intervention; Screening for key microbial taxa post - CMNT intervention based on gut microbiota results; Validation of the causal relationship between diet and gut microbiota using fecal transplantation; Rationale: Incorporating gut microbiota and metabolomics indicators helps better explore the mechanism of CMNT dietary intervention in this population. 5. The participant recruitment period has been extended to May 5, 2026. Rationale: Due to the severe COVID-19 pandemic during 2022-2023, coupled with the fact that this study focuses on comorbidities, the number of eligible participants has been significantly lower compared to studies involving general T2D patients. Furthermore, as most individuals currently do not prioritize fatty liver screening, participant recruitment has progressed more slowly than anticipated. Therefore, an extension of the recruitment period is necessary.
Interventions
OTHERCMNT diet
Hypocaloric CMNT diet plan: A diet plan with intermittent use of enriched traditional-Chinese-medicinal-foods CMNT diet
Sponsors
State Key Laboratory of Subhealth Intervention Technology
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with type 2 diabetes and NAFLD. * Age between 18 and 75 years. * Body mass index (BMI) \> 18.0 kg/m2 * Weight stable for at least 3 months prior to the study (gain or loss \<4kg). * Stable treatment for at least 3 months with 1-3 oral * antidiabetic medications (with or without insulin therapy), or not yet receiving antidiabetic medication prior to the beginning of the study. * Able to give written informed consent.
Exclusion criteria
* Participants meeting any of the following criteria will not be allowed to participate in the trial: * Use of any of the following medications or treatments: * Use of other medications that may affect glucose metabolism within the past 2 months, including systemic glucocorticoids (excluding inhaled or topical use), growth hormones, etc.; * Use of antihypertensive or lipid-lowering medications that have not reached a stable dosage before screening; * Presence of any of the following medical histories or conditions: * History or presence of any cardiac disease within the past 6 months; * Decompensated heart failure (NYHA Class III or IV); * Unstable angina, myocardial infarction, coronary artery bypass grafting, or coronary stenting; * Uncontrolled or severe arrhythmias (e.g., long QT syndrome), as assessed by the investigator as unsuitable for trial participation; * History of hemorrhagic or ischemic stroke within the past 6 months, as assessed by the investigator as unsuitable for trial participation; * Medical history of cerebral thrombosis, cerebral vascular blockage, encephalic angioma, transient ischemic attack, cerebral hemorrhage, stroke, hydrocephalus, or malignant brain tumor; * History of carotid artery stenting; * Urinary system conditions such as nephrotic syndrome, uremia, polycystic kidney disease, kidney transplantation, unilateral nephrectomy/congenital solitary kidney, renal atrophy, renal tumor; * Digestive system conditions such as ascites, liver cirrhosis, liver fluke infection, severe hepatitis, gastric varices; * Nervous system conditions such as cerebellar atrophy, demyelinating diseases, cerebral palsy, Parkinson's disease, mania, schizophrenia; * Respiratory system conditions such as pulmonary embolism, cor pulmonale; * Musculoskeletal system conditions such as arterial rupture, myeloma; * Immune system conditions such as Behçet's disease, lupus erythematosus; * Conditions such as chondrosarcoma, liposarcoma, brucellosis, leukemia; * History of malignant tumor within the past 5 years, or currently under evaluation for potential malignancy; * History of unstable or treatment-requiring proliferative retinopathy or macular edema within the past 6 months; * History of diabetic ketoacidosis or hyperosmolar nonketotic diabetic coma within the past 6 months; * Currently suffering from lower extremity arteriosclerotic occlusive disease; History of severe infection or severe trauma within the past 1 month; * History of ≥2 severe hypoglycemic episodes within the past year; * Currently suffering from clinically significant urinary tract/genital infection, or a history of complicated urinary tract infections, or recurrent urinary tract infections within the past 6 months; * Currently suffering from uncontrolled hypertension, defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg at screening/baseline, or systolic blood pressure ≤90 mmHg and/or diastolic blood pressure ≤60 mmHg; * Currently suffering from uncontrolled thyroid dysfunction; * History of other severe endocrine diseases, such as multiple endocrine neoplasia; * History of severe hepatic or renal disease; * Suspected or confirmed history of alcohol or drug abuse; * Blood donation or blood loss ≥400 mL within the past 3 months; * Presence of severe psychiatric disorders or language barriers, unwillingness or inability to fully understand and cooperate; * Pregnant or breastfeeding women; * Any other conditions deemed unsuitable for trial participation by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Controlled attenuation parameter (CAP) value by transient elastography | 3, 6, 12, 24 months | The CAP score, which be measured by FibroScan, will be used to quantify and detect liver fat. CAP \< 238 dB/m indicated no hepatic steatosis, 238 ≤ CAP ≤ 259 dB/m denoted mild steatosis, 260 ≤ CAP ≤291 dB/m indicated moderate steatosis, and CAP \> 291 dB/m denoted severe steatosis. |
| HbA1C | 3, 6, 12, 24 months | Blood test to measure glucose control |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fasting blood glucose | 3, 6, 12, 24 months | Fasting blood glucose (mmol/L) will be assessed among Glycemic Homeostasis Parameters |
| Fasting insulin | 3, 6, 12, 24 months | Fasting insulin (μIU/mL) will be assessed among Glycemic Homeostasis Parameters |
| Blood lipid | 3, 6, 12, 24 months | triglyceride, total cholesterol, low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein-cholesterol (HDL-C) |
| Liver fibrosis markers | 3, 6, 12, 24 months | Liver stiffness measurement (LSM) value by transient elastography DiabetesLiver score Fibrotic non-alcoholic steatohepatitis index (FNI) Fibrosis-4 index (FIB-4) NAFLD fibrosis score (NFS) |
| γ-GGT | 3, 6, 12, 24 months | γ-glutamyl transferase (γ-GGT) will be assessed for liver function tests |
| Food Frequency Questionnaire (FFQ) | 3, 6, 12, 24 months | The Food Frequency Questionnaire (FFQ) typically estimates nutrient intake based on food consumption frequency, with a common range of 800-5000 kcal/day for adults. |
| Metabolomics | 3, 6, 12, 24 months | Concentration of Key Serum Metabolites Identified by Metabolomics Before and After CMNT Intervention in All Participants |
| Gut microbiota | 3, 6, 12, 24 months | Change in Gut Microbiota Composition (Relative Abundance at species Level) Before and After CMNT Intervention in All Participants |
| Hepatic steatosis Markers | 3, 6, 12, 24 months | Fatty liver index (FLI) Hepatic steatosis index (HSI) |
| Body Mass Index (BMI) | 3, 6, 12, 24 months | Body Mass Index (BMI) will be measured as an anthropometric parameter (kg/m²) |
Countries
China
Contacts
Primary ContactWu Luo
Outcome results
None listed